It is worth mentioning that consistent CVD benefits observed with anti-inflammatory therapies targeting the IL-1 pathway [157, 158], as demonstrated in studies like the LoDoCo2 trial and investigations into anti-IL-1 therapy, underscore the efficacy of these treatments across patient cohorts, regardless of T2DM status. Here, IL1B is linked to type 2 diabetes mellitus.